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INTRODUCTION
Nephrogenic diabetes insipidus (NDI) is a rare disease
that is characterized by the excretion of abnormally large
volumes of urine, due to the inability of the kidneys to
concentrate urine in response to arginine vasopressin
(AVP). Classical NDI symptoms include polydipsia and
polyuria in infants during the first year of life. Acquired
NDI is the most common form of this disease in adults. The
majority of inherited cases are caused by mutations in the
arginine vasopressin V2 receptor (AVPR2) gene (MIM#
300538) on chromosome Xq28, which leads to functional
defects in the AVPR2. The aquaporin (AQP2) gene (MIM#
107777) on chromosome 12q13 (1) is associated with the
disease (2,3) in the minority of cases (,10%). The present
study identified two novel compound heterozygous muta-
tions in the AQP2 gene, H201Y and G211R, in one female
patient with congenital NDI.
CASE REPORT
A breastfeeding two-month-old girl was admitted to the
emergency room after 12 days of fever of unknown origin
and weight loss. The patient had received 20 mgo f1 -
desamino[8-D-arginine]vasopressin (dDAVP) intranasally,
but this intervention did not decrease her urine output.
Physical examination revealed a severely dehydrated and
highly irritable infant with no other clinical abnormalities.
The infant’s height-for-age ratio was in the 3
rd percentile,
and her initial laboratory profile revealed hypernatremia
(172 mEq/ml) and a low urine density (1.005). The patient’s
basal sodium was within the normal range after an increase
in her fluid intake and a low sodium diet, and she was
subjected to laboratory investigation to ascertain the
diagnosis of NDI according to established criteria (4). A
short water deprivation test was performed under a strictly
controlled medical setting, but this test was stopped six
hours later because of weight loss (3%). Her urinary
osmolality was 263 mOsmol/kg at six hours and increased
to 300 mOsmol/kg one hour after dDAVP administration
(20 mg intranasally). The patient was allowed water after the
administration of dDAVP. The T1-weighted images from a
brain MRI did not reveal the hyperintense signal that is
normally emitted by the posterior pituitary gland (i.e., there
was no ‘‘bright spot’’). The child’s parents were also
subjected to diagnostic procedures to exclude nephrogenic
diabetes insipidus. The patient was the second child of a
healthy young and non-consanguineous couple with no
diabetes insipidus symptoms. The patient was a postferti-
lization baby for whom the female sex had been chosen, and
her older brother had hemophilia. The family pedigree is
shown in Figure 1a. Hydrochlorothiazide (5 mg/kg/twice
daily) and amiloride (20 mg/m
2/day) were initiated, but
only a partial response was observed; namely, the patient’s
basal urine osmolality increased to 456 mOsmol/kg two
weeks after the initiation of these two medications. A
remission of symptoms occurred when indomethacin
(1.0 mg/kg/day) was subsequently added. Two weeks after
initial administration of this medication, the patient’s urine
osmolality rose to 587 mOsmol/kg. The patient’s height-for-
age ratio was in the 50
th percentile at age four, while she was
under careful surveillance and receiving medications.
The parents signed an informed consent that was
approved by the Institutional Ethics Committee in accor-
dance with the ethical standards of the 1964 Declaration of
Helsinki.
MATERIALS AND METHODS
Whole blood cells were collected from the patient and her
parents for molecular analyses. Genomic DNA was isolated
using the Wizard Genome DNA Purification KitH (Promega,
Madison, WI) according to the manufacturer’s instructions.
All coding and flanking regions of all exons of the AVPR2
gene were amplified by PCR using previously described
sets of primers (5). The AQP2 gene oligonucleotides
included the following sequences: exon 1, forward CA-
TCCTGGCCCTGAGACA, reverse TACAAGGGATTCCC-
CAGGAC; exon 2, forward GACAGGAAGATGGA-
GCCAGA, reverse TGGAGTGGTCTGTGTGTCTGT; exon
3, forward ACAAGGACTTCCTGCCCTGT, reverse TCCC-
ATGCTATTCCAGCTCT; and exon 4, forward TAATGTC-
GGGGAGGAGAGGT, reverse CACGTCCAGGAAGCAG-
CTA. Briefly, PCR was performed in a final volume of 25 ml
containing IIB Buffer 10x, 0.2 mM dNTP, 10 pmol of each
primer, 0.625 U Taq polymerase and 60 ng/ml DNA. PCR
products were purified using the GFX PCR DNA and Gel
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79Purification Kit (Amersham Pharmacia Biotech, Piscataway,
NJ) according to the manufacturer’s instructions and
sequenced in an ABI PrismH 3130 Genetic Analyzer using
the ABI Prism Dye Terminator sequencing kit (Applied
Biosystems, Foster City, CA) according to the standard
protocol. Sequences were performed in the sense and
Figure 1 - (a) Pedigree of the Brazilian family with NDI; the proband is indicated by an arrow. An open square with an inset (N) indicates
that the individual was unaffected. (b) c.491T.C polymorphism; (c and e) heterozygosis at c.601C.T (H201Y) of the proband and her
mother; and (d and f) heterozygosis at c.697C.G (G211R) of the proband and her father.
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80antisense directions in duplicate using separate DNA
extractions.
RESULTS
A diagnosis of NDI due to mutations of the AVPR2 gene
was excluded based on the patient’s sex, although certain
female carriers have a partial response to dDAVP due to
skewed X-chromosome inactivation (6), and also based on
the direct sequencing of the entire coding and exon-flanking
gene regions, which demonstrated a wild-type sequence.
Sequencing analyses of all four AQP2 exons revealed that
the patient was a compound heterozygote with two novel
point mutations in exons 3 and 4. One point mutation was a
C-to-T transversion at position 601 (c.601C.T) in exon 3
(H201Y) (Figure 1c), which was inherited from her mother
(Figure 1e), and a C to G transition at position 697
(c.697C.G) in exon 4 (G211R) (Figure 1d), which was
inherited from her father (Figure 1f). A previously described
polymorphism at position 491 (c.491T.C; S167S) was also
present (Figure 1b). Neither parent exhibited any clinical or
biochemical signs of diabetes insipidus.
DISCUSSION
This report described two novel missense mutations in a
heterozygote female infant with inherited NDI. Severe
polyuria and polydipsia began soon after birth, and these
findings in association with the child’s sex and the failure of
dDAVP to relieve symptoms suggested that NDI was
caused by mutation(s) of the AQP2 gene. A full mutation
analysis of the AVP receptor gene demonstrated no germ-
line mutations. NDI that is caused by mutations in the AQP2
gene are inherited as either an autosomal recessive or a
dominant trait (7,8). The sequencing analyses of the AQP2
gene in our patient revealed a compound heterozygosity
that was inherited from both parents. Heterozygote muta-
tion carriers are not affected. Therefore, no clinically
important phenotype was expected or observed in the
patient’s parents. Interestingly, the patient’s height-for-age
ratio at age four was within the normal range. Patients with
mutations in the AQP2 gene have a short (9) or normal
stature (10,11). The response to therapy in this child was
notably better than the response of other patients with
autosomal-recessive NDI due to AQP2 gene mutations. The
reasons for this improved response are not known, but the
presence of a compound heterozygote mutation may
underlie this unusually good response.
The human AQP2 gene is located on chromosome 12q13.
This gene has four exons and three introns, and it is
predicted to code a 271-amino-acid protein. AQP2 is a single
polypeptide chain with six transmembrane domains, which
is similar to other aquaporins, and both terminal ends are
located inside the cell (3). The first intracellular and the third
extracellular loops contain the asparagine-proline-alanine
(NPA) motif that is conserved in all members of the
membrane integral protein (MIP) family. This motif may
play a role in the formation of functional water-selective
pores, but it is no longer thought to confer water selectivity
(12). In addition, the phosphorylation of serine at position
256 by PKA in the cytoplasmic COOH-terminus of AQP2 is
essential for its distribution from intracellular vesicles to the
apical plasma membrane (13,14).
To date, 66 distinct AQP2 gene mutations have been
described, and the vast majority (86%) of these mutations
are associated with an autosomal recessive mode of
transmission (MIM #125800). Several compound mutations
within this gene have also been described (6,9,11,15-19).
Most mutations in patients with autosomal-recessive NDI
are localized between the first and the last transmembrane
domains. This segment forms the AQP2 water pore, and the
mutation-induced misfolding illustrates the sensitivity of
the pore to structural changes (14). A compound recessive
mutation has been described previously in a female patient
in which one of the mutations was located in the conserved
region of the last transmembrane domain of AQP2, and this
mutation resulted in a misfolded protein (6).
The mutations in our analysis, H201Y and G211R, were
located on the extracellular and transmembrane domains,
respectively, and these domains are probably critical for
protein function. Both histidine 201 and glycine 211 are
highly conserved amino acids between species. The wild-
type glycine, which is the smallest amino acid, is located
next to proline, which is responsible for protein folding. The
mutations resulting from a substitution of tyrosine
(uncharged polar amino acid) for histidine and arginine
for glycine severely alter AQP2 structure and disrupt water
absorption.
In conclusion, this study described a compound hetero-
zygosity that was characterized by two novel mutations in
AQP2 exons 3 and 4 in an infant female patient. These
combined mutations probably caused a disruption in the
protein, but functional studies are necessary to understand
the effects of these mutations on AQP2.
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